Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ampio Pharmaceuticals, Inc. (AMPE)
USD0.18
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
373 Inverness Parkway 80112
Englewood, CO, US
Englewood, CO, US
CEO
Michael A. Martino
Website
ampiopharma.com
IPO
2010-03-31
CIK 1411906 ISIN US03209T3077
Description
Ampio Pharmaceuticals, Inc., headquartered in Englewood, Colorado, is a biopharmaceutical firm dedicated to advancing immunomodulatory therapeutics primarily for the management of osteoarthritis pain across the United States. Their developmental pipeline currently features several compounds: AP-013, an intra-articular injection, is undergoing Phase III clinical trials for knee osteoarthritis. Additionally, the company has multiple candidates addressing COVID-19: AP-017, an intravenous Ampion formulation, is in Phase II for adult COVID-19 patients who require supplemental oxygen; AP-019, an inhaled Ampion treatment, also in Phase II, targets adults experiencing respiratory distress from COVID-19; while AP-018, currently in Phase I, aims to treat individuals with persistent respiratory symptoms following COVID-19 infection.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| BioSciences | 2011-01-06 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.18
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
61
Beta
6.03
Float Shares
1.12M
Free Float %
98.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +3,421.15% | -36.86% | +3,421.15% | +3,421.15% | +6,003.33% | -96.84% | -99.97% | -99.80% | -99.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.18
DCF (Unlevered)
4.89
+2,572.3%
DCF (Levered)
4.71
+2,471.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-63.66
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+63.6% ★ Q4'23: +11.1% (vs Q4'22)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q4'23: -942.4% (vs Q4'22)
-
EBIT margin Biotechnology: +0.0%— Q4'23: -904.1% (vs Q4'22)
-
ROIC Biotechnology: -16.1%— Q4'23: +1,947.3% (vs Q4'22)
-
Share dilution Biotechnology: -3.4%+7.5% Q4'23: +10.1% (vs Q4'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q4'23: -0.03× (vs Q4'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
50.0K
est: 34.2K (+46.3%)
|
76.8K
est: 82.6K (-7.0%)
|
1.16M
est: 86.0K (+1,251.2%)
|
—
est: 100.0K (-100.0%)
|
—
est: 100.0K (-100.0%)
|
—
est: 1.80M (-100.0%)
|
—
|
—
est.
|
| EBITDA |
-23.89M
est: -19.20M (-24.4%)
|
-31.11M
est: -38.40M (+19.0%)
|
-23.34M
|
-14.81M
|
-14.46M
|
35.26M
|
-8.38M
|
—
est.
|
| EBIT |
-24.02M
est: -19.29M (-24.5%)
|
-31.45M
est: -39.84M (+21.1%)
|
—
|
—
|
-15.57M
|
33.98M
|
-8.63M
|
—
est.
|
| Net Income |
-24.01M
est: -19.31M (-24.3%)
|
-38.13M
est: -38.85M (+1.9%)
|
-32.01M
est: -149.10M (+78.5%)
|
-19.16M
est: -45.47M (+57.9%)
|
-51.89M
est: 56.70M (-191.5%)
|
33.99M
est: -352.40M (+109.6%)
|
-8.63M
est: -19.44M (+55.6%)
|
-29.16M
est.
|
| SGA |
7.48M
|
12.23M
|
9.06M
|
6.54M
|
5.14M
|
4.36M
|
6.95M
|
—
est.
|
| EPS |
-189.00
est: -0.45 (-42,371.9%)
|
-228.00
est: -0.91 (-24,954.9%)
|
-184.70
est: -184.05 (-0.4%)
|
-107.06
est: -56.13 (-90.8%)
|
-239.13
est: 69.99 (-441.7%)
|
92.10
est: -435.00 (+121.2%)
|
-10.67
est: -24.00 (+55.5%)
|
-36.00
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-14.09M
OE per share TTM
-20.87
Owner's Yield
-9,315.52%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
3,741.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
67.00
Insider transactions (90d)
0
Beneficial owners (>5%)
13
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bruce E. Terker | 14.40M | 6.34% | — | 14.40M | — | 14.40M | IN | Pennsylvania | 2022-04-29 | ↗ |
| 2 | IDENTIFICATION NOS. OF ABOVE PERSONS ( | 5.91M | 2.60% | — | 5.91M | — | 5.91M | PN | Pennsylvania | 2022-04-29 | ↗ |
| 3 | CVI Investments, Inc. | 5.60M | 4.90% | — | 5.60M | — | 5.60M | CO | Cayman Islands | 2019-02-14 | ↗ |
| 4 | Heights Capital Management, Inc. | 5.60M | 4.90% | — | 5.60M | — | 5.60M | CO | Delaware | 2019-02-14 | ↗ |
| 5 | (1) BlackRock, Inc. | 4.70M | 2.10% | 4.69M | — | 4.70M | — | HC | Delaware | 2022-07-08 | ↗ |
| 6 | Carol G. Frankenfield | 4.15M | 5.50% | 75.0K | 1.06M | — | — | IN | Delaware | 2017-10-27 | ↗ |
| 7 | 2 | 3.27M | 2.95% | — | 3.27M | — | 3.27M | PN | Pennsylvania | 2019-02-01 | ↗ |
| 8 | Empery Asset Management, LP | 2.83M | 8.84% | — | 2.83M | — | — | PN | Delaware | 2019-06-20 | ↗ |
| 9 | Martin D. Hoe | 2.83M | 8.84% | — | 2.83M | — | — | IN | United States | 2019-06-20 | ↗ |
| 10 | Ryan M. Lane | 2.83M | 8.84% | — | 2.83M | — | — | IN | United States | 2019-06-20 | ↗ |
| 11 | Empery Tax Efficient II, LP | 1.83M | 1.15% | — | 1.83M | — | 1.83M | PN | Delaware | 2020-01-23 | ↗ |
| 12 | ( | 1.21M | 1.40% | 197.6K | — | 197.6K | — | PN | Delaware | 2018-08-10 | ↗ |
| 13 | Amir L. Ecker | 1.21M | 1.40% | 907.1K | 1.10M | — | — | IN | Delaware | 2018-08-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CYPRESS CAPITAL MANAGEMENT LLC (WY) | 440.00 +— (+0.0%) | 67.00 +65.0 (+3,250.0%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD— | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
296.9K
Shares disposed
—
Cash buys
8.00
Cash sales
—
Net activity
+296,890
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-09 | BUCHI J KEVIN | Director | P-Purchase | A | Common Stock | 21,858 | 0.29 | 6.3K | 146,858 | — | ↗ |
| 2023-06-08 | BUCHI J KEVIN | Director | P-Purchase | A | Common Stock | 25,000 | 0.30 | 7.4K | 125,000 | — | ↗ |
| 2023-05-24 | MARTINO MICHAEL A | Director / Officer | P-Purchase | A | Common Stock | 76,890 | 0.29 | 22.1K | 76,890 | — | ↗ |
| 2023-05-16 | BUCHI J KEVIN | Director | P-Purchase | A | Common Stock | 32,534 | 0.27 | 8.9K | 100,000 | — | ↗ |
| 2023-05-15 | BUCHI J KEVIN | Director | P-Purchase | A | Common Stock | 44,026 | 0.25 | 10.9K | 67,466 | — | ↗ |
| 2023-05-12 | Stevens David R | Director | P-Purchase | A | Common Stock | 45,000 | 0.22 | 9.9K | 103,971 | — | ↗ |
| 2023-05-12 | BUCHI J KEVIN | Director | P-Purchase | A | Common Stock | 23,440 | 0.24 | 5.5K | 23,440 | — | ↗ |
| 2023-05-11 | Stevens David R | Director | P-Purchase | A | Common Stock | 25,000 | 0.22 | 5.4K | 58,971 | — | ↗ |
| 2022-03-01 | JOBES ELIZABETH VARKI | Director | A-Award | A | Stock Option (Right to Buy) | 150,000 | 0.45 | 67.7K | 150,000 | — | ↗ |
| 2022-02-09 | Bar-Or David | Director | A-Award | A | Stock Option (right to buy) | 75,000 | 0.53 | 39.7K | 75,000 | — | ↗ |
| 2022-02-08 | JOBES ELIZABETH VARKI | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-01 | STOKELY DAN | Officer | F-InKind | D | Common Stock | 22,914 | 0.57 | 13.1K | 312,274 | — | ↗ |
| 2022-01-01 | MARTINO MICHAEL A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 0.57 | 142.5K | 250,000 | — | ↗ |
| 2022-01-01 | MACALUSO MICHAEL | Director | F-InKind | D | Common Stock | 68,400 | 0.57 | 39.0K | 2,624,882 | — | ↗ |
| 2022-01-01 | Cherevka Holli | Officer | F-InKind | D | Common Stock | 47,200 | 0.57 | 26.9K | 410,820 | — | ↗ |
| 2021-12-30 | Stevens David R | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.56 | 42.0K | 75,000 | — | ↗ |
| 2021-12-30 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.56 | 42.0K | 75,000 | — | ↗ |
| 2021-12-30 | COELHO PHILIP H | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.56 | 42.0K | 75,000 | — | ↗ |
| 2021-12-30 | BUCHI J KEVIN | Director | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.56 | 42.0K | 75,000 | — | ↗ |
| 2021-11-22 | MARTINO MICHAEL A | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 1.14 | 855.0K | 750,000 | — | ↗ |
| 2021-10-27 | STOKELY DAN | Officer | F-InKind | D | Common Stock | 28,127 | 1.64 | 46.1K | 335,188 | — | ↗ |
| 2021-10-27 | MACALUSO MICHAEL | Director / Officer | F-InKind | D | Common Stock | 43,470 | 1.64 | 71.3K | 2,693,282 | — | ↗ |
| 2021-10-27 | Cherevka Holli | Officer | F-InKind | D | Common Stock | 41,980 | 1.64 | 68.8K | 458,020 | — | ↗ |
| 2021-10-21 | MARTINO MICHAEL A | Director | A-Award | A | Stock Option (Right to Buy) | 150,000 | 1.67 | 250.5K | 150,000 | — | ↗ |
| 2021-10-21 | BUCHI J KEVIN | Director | A-Award | A | Stock Option (Right to Buy) | 150,000 | 1.67 | 250.5K | 150,000 | — | ↗ |
| 2021-10-13 | Stevens David R | Director | A-Award | A | Stock Option (Right to Buy) | 120,000 | 1.67 | 200.4K | 120,000 | — | ↗ |
| 2021-10-13 | MARTINO MICHAEL A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-13 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 120,000 | 1.67 | 200.4K | 120,000 | — | ↗ |
| 2021-10-13 | COELHO PHILIP H | Director | A-Award | A | Stock Option (Right to Buy) | 120,000 | 1.67 | 200.4K | 120,000 | — | ↗ |
| 2021-10-13 | Bar-Or David | Director | A-Award | A | Stock Option (right to buy) | 120,000 | 1.67 | 200.4K | 120,000 | — | ↗ |
| 2021-10-13 | BUCHI J KEVIN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-11 | STOKELY DAN | Officer | A-Award | A | Common Stock | 335,000 | 0.00 | — | 363,315 | — | ↗ |
| 2021-10-11 | MACALUSO MICHAEL | Director / Officer | A-Award | A | Common Stock | 950,000 | 0.00 | — | 2,736,752 | — | ↗ |
| 2021-10-11 | Cherevka Holli | Officer | A-Award | A | Common Stock | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2021-06-25 | STOKELY DAN | Officer | M-Exempt | D | 1. Stock Option (Right to Buy) | 22,500 | 0.43 | 9.7K | 260,500 | — | ↗ |
| 2021-05-21 | Cherevka Holli | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,603 | 0.51 | 1.3K | 152,766 | — | ↗ |
| 2021-05-21 | COELHO PHILIP H | Director | M-Exempt | D | Stock Option (Right to Buy) | 6,737 | 0.40 | 2.7K | 0 | — | ↗ |
| 2021-05-18 | STOKELY DAN | Officer | S-Sale | D | Common Stock | 35,000 | 1.83 | 64.0K | 28,315 | — | ↗ |
| 2021-05-17 | STOKELY DAN | Officer | M-Exempt | D | Stock Option (Right to Buy) | 35,000 | 0.43 | 15.1K | 283,000 | — | ↗ |
| 2021-04-29 | COELHO PHILIP H | Director | M-Exempt | A | Common Stock | 3,263 | 0.40 | 1.3K | 206,763 | — | ↗ |
| 2021-04-27 | Cherevka Holli | Officer | M-Exempt | D | Stock Option (Right to Buy) | 30,000 | 0.51 | 15.3K | 0 | — | ↗ |
| 2021-04-27 | COELHO PHILIP H | Director | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 0.40 | 8.0K | 10,000 | — | ↗ |
| 2021-03-16 | STOKELY DAN | Officer | M-Exempt | D | Stock Option (Right to Buy) | 40,000 | 0.43 | 17.2K | 318,000 | — | ↗ |
| 2021-02-12 | STOKELY DAN | Officer | M-Exempt | A | Common Stock | 42,000 | 2.55 | 107.1K | 42,000 | — | ↗ |
| 2021-01-04 | Stevens David R | Director | A-Award | A | Common Stock | 13,513 | 1.48 | 20.0K | 134,562 | — | ↗ |
| 2021-01-04 | Giles Richard B | Director | A-Award | A | Common Stock | 13,513 | 1.48 | 20.0K | 314,866 | — | ↗ |
| 2021-01-04 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 13,513 | 1.48 | 20.0K | 203,500 | — | ↗ |
| 2021-01-04 | Bar-Or David | Director | A-Award | A | Common Stock | 13,513 | 1.48 | 20.0K | 92,800 | — | ↗ |
| 2020-12-17 | STOKELY DAN | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.78 | 35.6K | 20,000 | — | ↗ |
| 2020-12-17 | MACALUSO MICHAEL | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.78 | 89.0K | 50,000 | — | ↗ |
| 2020-12-17 | Cherevka Holli | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.78 | 97.9K | 65,000 | — | ↗ |
| 2020-12-12 | Stevens David R | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 1.50 | 54.0K | 36,000 | — | ↗ |
| 2020-12-12 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 1.50 | 54.0K | 36,000 | — | ↗ |
| 2020-12-12 | COELHO PHILIP H | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 1.50 | 54.0K | 36,000 | — | ↗ |
| 2020-12-12 | Bar-Or David | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 1.50 | 54.0K | 36,000 | — | ↗ |
| 2020-11-18 | Bar-Or David | Director | A-Award | A | Stock Option (right to buy) | 300,000 | 0.79 | 235.8K | 300,000 | — | ↗ |
| 2020-07-01 | MACALUSO MICHAEL | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 255,000 | 0.65 | 165.8K | 255,000 | — | ↗ |
| 2020-07-01 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 212,500 | 0.65 | 138.1K | 212,500 | — | ↗ |
| 2020-07-01 | COELHO PHILIP H | Director | A-Award | A | Stock Option (Right to Buy) | 136,471 | 0.65 | 88.7K | 136,471 | — | ↗ |
| 2020-07-01 | Bar-Or David | Director | A-Award | A | Stock Option (right to buy) | 200,000 | 0.61 | 122.0K | 200,000 | — | ↗ |
| 2020-01-10 | MACALUSO MICHAEL | Officer | A-Award | A | Option (Right to Buy) | 200,000 | 0.68 | 135.6K | 200,000 | — | ↗ |
| 2020-01-02 | Stevens David R | Director | A-Award | A | Common Stock | 34,059 | 0.59 | 20.0K | 121,049 | — | ↗ |
| 2020-01-02 | STOKELY DAN | Officer | A-Award | A | Option (Right to Buy) | 30,000 | 0.59 | 17.6K | 30,000 | — | ↗ |
| 2020-01-02 | Giles Richard B | Director | A-Award | A | Common Stock | 34,059 | 0.59 | 20.0K | 301,353 | — | ↗ |
| 2020-01-02 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 34,059 | 0.59 | 20.0K | 189,987 | — | ↗ |
| 2020-01-02 | Bar-Or David | Director | A-Award | A | Common Stock | 34,059 | 0.59 | 20.0K | 79,287 | — | ↗ |
| 2019-12-19 | Stevens David R | Director | A-Award | A | Option (Right to Buy) | 36,000 | 0.47 | 16.7K | 36,000 | — | ↗ |
| 2019-12-19 | Giles Richard B | Director | A-Award | A | Option (Right to Buy) | 36,000 | 0.47 | 16.7K | 36,000 | — | ↗ |
| 2019-12-19 | COELHO PHILIP H | Director | A-Award | A | Option (Right to Buy) | 36,000 | 0.47 | 16.7K | 36,000 | — | ↗ |
| 2019-12-19 | Bar-Or David | Director | A-Award | A | Option (Right to Buy) | 36,000 | 0.47 | 16.7K | 36,000 | — | ↗ |
| 2019-10-17 | Bar-Or David | Director | A-Award | A | Common Stock | 45,228 | 0.44 | 20.0K | 45,228 | — | ↗ |
| 2019-09-16 | Cherevka Holli | Officer | A-Award | A | Option (Right to Buy) | 200,000 | 0.51 | 102.0K | 200,000 | — | ↗ |
| 2019-09-09 | Stevens David R | Director | A-Award | A | Stock Option (Right to Buy) | 216,750 | 0.75 | 162.6K | 0 | — | ↗ |
| 2019-09-09 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 365,500 | 0.75 | 274.1K | 0 | — | ↗ |
| 2019-09-09 | COELHO PHILIP H | Director | A-Award | A | Stock Option (Right to Buy) | 369,750 | 0.75 | 277.3K | 0 | — | ↗ |
| 2019-08-20 | STOKELY DAN | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 0.43 | 172.0K | 400,000 | — | ↗ |
| 2019-07-31 | STOKELY DAN | Officer | A-Award | A | Stock Option (Right to Buy) | 430,000 | 0.39 | 167.1K | 430,000 | — | ↗ |
| 2019-01-02 | Stevens David R | Director | A-Award | A | Common Stock | 45,454 | 0.44 | 20.0K | 86,990 | — | ↗ |
| 2019-01-02 | Giles Richard B | Director | A-Award | A | Common Stock | 45,454 | 0.44 | 20.0K | 267,294 | — | ↗ |
| 2019-01-02 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 45,454 | 0.44 | 20.0K | 155,928 | — | ↗ |
| 2018-12-15 | Stevens David R | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.40 | 12.0K | 30,000 | — | ↗ |
| 2018-12-15 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.40 | 12.0K | 30,000 | — | ↗ |
| 2018-12-15 | COELHO PHILIP H | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.40 | 12.0K | 30,000 | — | ↗ |
| 2018-10-01 | Chilcott, III Thomas E. | Officer | D-Return | D | Stock Option (Right to Buy) | 75,000 | 0.94 | 70.5K | 0 | — | ↗ |
| 2018-10-01 | Cherevka Holli | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 45,000 | 4.72 | 212.4K | 0 | — | ↗ |
| 2018-09-20 | Chilcott, III Thomas E. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.51 | 38.3K | 75,000 | — | ↗ |
| 2018-01-25 | Stevens David R | Director | A-Award | A | Common Stock | 5,747 | 3.48 | 20.0K | 41,536 | — | ↗ |
| 2018-01-25 | Giles Richard B | Director | A-Award | A | Common Stock | 5,747 | 3.48 | 20.0K | 221,840 | — | ↗ |
| 2018-01-25 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 5,747 | 3.48 | 20.0K | 110,474 | — | ↗ |
| 2017-09-27 | COELHO PHILIP H | Director | P-Purchase | A | Common Stock | 10,000 | 0.63 | 6.3K | 104,727 | — | ↗ |
| 2017-09-23 | Stevens David R | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.60 | 18.0K | 30,000 | — | ↗ |
| 2017-09-23 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.60 | 18.0K | 30,000 | — | ↗ |
| 2017-09-23 | COELHO PHILIP H | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.60 | 18.0K | 30,000 | — | ↗ |
| 2017-09-22 | COELHO PHILIP H | Director | P-Purchase | A | Common Stock | 3,000 | 0.60 | 1.8K | 94,727 | — | ↗ |
| 2017-09-20 | COELHO PHILIP H | Director | P-Purchase | A | Common Stock | 1,000 | 0.59 | 591.80 | 91,727 | — | ↗ |
| 2017-09-19 | Cherevka Holli | Officer | — | D | Stock Option (Right to Buy) | 35,000 | 4.16 | 145.6K | 0 | — | ↗ |
| 2017-09-19 | COELHO PHILIP H | Director | P-Purchase | A | Common Stock | 15,000 | 0.57 | 8.5K | 90,727 | — | ↗ |
| 2017-09-05 | COELHO PHILIP H | Director | P-Purchase | A | Common Stock | 30,000 | 0.56 | 16.8K | 75,727 | — | ↗ |
| 2017-08-28 | Bar-Or David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 133,000 | 0.50 | 66.5K | 133,000 | — | ↗ |
| 2017-08-23 | Chilcott, III Thomas E. | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.48 | 96.0K | 200,000 | — | ↗ |
| 2017-06-12 | Chilcott, III Thomas E. | Officer | — | D | Stock Option (right to buy) | 100,000 | 0.60 | 60.0K | 0 | — | ↗ |
| 2017-03-09 | MACALUSO MICHAEL | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 0.81 | 324.0K | 400,000 | — | ↗ |
| 2017-01-07 | Stevens David R | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.95 | 28.5K | 30,000 | — | ↗ |
| 2017-01-07 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.95 | 28.5K | 30,000 | — | ↗ |
| 2017-01-07 | COELHO PHILIP H | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.95 | 28.5K | 30,000 | — | ↗ |
| 2017-01-03 | Stevens David R | Director | A-Award | A | Common Stock | 20,826 | 0.96 | 20.0K | 35,789 | — | ↗ |
| 2017-01-03 | Giles Richard B | Director | A-Award | A | Common Stock | 20,826 | 0.96 | 20.0K | 216,093 | — | ↗ |
| 2017-01-03 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 20,826 | 0.96 | 20.0K | 45,727 | — | ↗ |
| 2016-07-15 | Gould Gregory A | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 1.03 | 154.5K | 416,666 | — | ↗ |
| 2016-01-04 | Stevens David R | Director | A-Award | A | Common Stock | 6,042 | 3.31 | 20.0K | 14,963 | — | ↗ |
| 2016-01-04 | Giles Richard B | Director | A-Award | A | Common Stock | 6,042 | 3.31 | 20.0K | 195,267 | — | ↗ |
| 2016-01-04 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 6,042 | 3.31 | 20.0K | 24,901 | — | ↗ |
| 2015-12-12 | Stevens David R | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.33 | 99.9K | 30,000 | — | ↗ |
| 2015-12-12 | Giles Richard B | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.33 | 99.9K | 30,000 | — | ↗ |
| 2015-12-12 | COELHO PHILIP H | Director | D-Return | D | Stock Option (Right to Buy) | 30,000 | 3.33 | 99.9K | 0 | — | ↗ |
| 2015-08-03 | Bar-Or David | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 2.60 | 780.0K | 300,000 | — | ↗ |
| 2015-07-31 | CLIFT VAUGHAN LENNOX | Officer | A-Award | A | Stock Option (right to buy) | 170,000 | 2.68 | 455.6K | 170,000 | — | ↗ |
| 2015-07-30 | Gould Gregory A | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 2.60 | 260.0K | 100,000 | — | ↗ |
| 2015-01-02 | Stevens David R | Director | A-Award | A | Common Stock | 2,666 | 3.75 | 10.0K | 8,921 | — | ↗ |
| 2015-01-02 | Giles Richard B | Director | A-Award | A | Common Stock | 2,666 | 3.75 | 10.0K | 189,225 | — | ↗ |
| 2015-01-02 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 2,666 | 3.75 | 10.0K | 18,859 | — | ↗ |
| 2014-12-31 | CLIFT VAUGHAN LENNOX | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-12-20 | MACALUSO MICHAEL | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 3.46 | 1.38M | 400,000 | — | ↗ |
| 2014-12-20 | COELHO PHILIP H | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.46 | 173.0K | 50,000 | — | ↗ |
| 2014-08-11 | CLIFT VAUGHAN LENNOX | Officer | A-Award | A | Stock Option (right to buy) | 170,000 | 6.48 | 1.10M | 170,000 | — | ↗ |
| 2014-08-11 | Bar-Or David | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 6.48 | 1.94M | 300,000 | — | ↗ |
| 2014-06-10 | Gould Gregory A | Officer | — | D | Stock Option (right to buy) | 300,000 | 7.14 | 2.14M | 0 | — | ↗ |
| 2014-06-08 | Giles Richard B | Director | D-Return | D | Stock Option (Right to Buy) | 70,000 | 6.96 | 487.2K | 0 | — | ↗ |
| 2014-01-02 | Stevens David R | Director | A-Award | A | Common Stock | 1,403 | 7.13 | 10.0K | 6,255 | — | ↗ |
| 2014-01-02 | Giles Richard B | Director | A-Award | A | Common Stock | 1,403 | 7.13 | 10.0K | 186,559 | — | ↗ |
| 2014-01-02 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 1,403 | 7.13 | 10.0K | 16,193 | — | ↗ |
| 2013-12-03 | Giles Richard B | Director | X-InTheMoney | D | Warrant to purchase common stock (right to buy) | 11,918 | 1.75 | 20.9K | 0 | — | ↗ |
| 2013-11-27 | MACALUSO MICHAEL | Director / Officer | X-InTheMoney | D | Warrant to purchase common stock (right to buy) | 27,379 | 1.75 | 47.9K | 0 | — | ↗ |
| 2013-11-18 | COELHO PHILIP H | Director | S-Sale | D | Common Stock | 13,287 | 8.25 | 109.7K | 14,790 | — | ↗ |
| 2013-11-15 | COELHO PHILIP H | Director | S-Sale | D | Common Stock | 11,320 | 8.22 | 93.1K | 28,077 | — | ↗ |
| 2013-11-11 | Bar-Or David | Director / Officer | G-Gift | D | Common Stock | 2,700,000 | 0.00 | — | 0 | — | ↗ |
| 2013-11-08 | McGregor Mark D | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 8.62 | 862.0K | 100,000 | — | ↗ |
| 2013-10-01 | MACALUSO MICHAEL | Director / Officer | G-Gift | D | Common Stock | 142,000 | 0.00 | — | 1,901,373 | — | ↗ |
| 2013-07-15 | CLIFT VAUGHAN LENNOX | Officer | A-Award | A | Stock Option (right to buy) | 170,000 | 6.15 | 1.05M | 170,000 | — | ↗ |
| 2013-07-15 | Bar-Or David | Director / Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 6.15 | 1.85M | 300,000 | — | ↗ |
| 2013-03-07 | Giles Richard B | Director | A-Award | A | Stock Option (right to buy) | 80,000 | 3.95 | 316.0K | 80,000 | — | ↗ |
| 2013-01-18 | Giles Richard B | Director | M-Exempt | A | Common Stock | 10,417 | 2.76 | 28.8K | 50,417 | — | ↗ |
| 2013-01-02 | Stevens David R | Director | A-Award | A | Common Stock | 2,584 | 3.87 | 10.0K | 4,852 | — | ↗ |
| 2013-01-02 | Giles Richard B | Director | A-Award | A | Common Stock | 2,584 | 3.87 | 10.0K | 175,076 | — | ↗ |
| 2013-01-02 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 2,584 | 3.87 | 10.0K | 39,397 | — | ↗ |
| 2012-12-15 | Disbrow Joshua R. | Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 3.53 | 1.41M | 400,000 | — | ↗ |
| 2012-05-07 | Stevens David R | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 2.76 | 276.0K | 100,000 | — | ↗ |
| 2012-05-07 | McGregor Mark D | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 2.76 | 207.0K | 75,000 | — | ↗ |
| 2012-05-07 | MACALUSO MICHAEL | Director / Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 2.76 | 690.0K | 250,000 | — | ↗ |
| 2012-05-07 | Giles Richard B | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 2.76 | 276.0K | 100,000 | — | ↗ |
| 2012-05-07 | COELHO PHILIP H | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 2.76 | 276.0K | 100,000 | — | ↗ |
| 2012-05-07 | CLIFT VAUGHAN LENNOX | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 2.76 | 414.0K | 150,000 | — | ↗ |
| 2012-05-07 | Bar-Or David | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 2.76 | 552.0K | 200,000 | — | ↗ |
| 2012-01-17 | Giles Richard B | Director | A-Award | A | Common Stock | 367 | 2.97 | 1.1K | 172,475 | — | ↗ |
| 2012-01-13 | Stevens David R | Director | A-Award | A | Common Stock | 2,268 | 4.41 | 10.0K | 2,268 | — | ↗ |
| 2012-01-13 | MACALUSO MICHAEL | Director / Officer | A-Award | A | Common Stock | 2,268 | 4.41 | 10.0K | 2,043,373 | — | ↗ |
| 2012-01-13 | Giles Richard B | Director | A-Award | A | Common Stock | 2,268 | 4.41 | 10.0K | 172,108 | — | ↗ |
| 2012-01-13 | COELHO PHILIP H | Director | A-Award | A | Common Stock | 2,268 | 4.41 | 10.0K | 36,813 | — | ↗ |
| 2011-11-22 | COELHO PHILIP H | Director | M-Exempt | D | Stock Option (right to buy) | 34,446 | 1.03 | 35.5K | 160,554 | — | ↗ |
| 2011-08-29 | Stevens David R | Director | D-Return | D | Stock Option (Right to Buy) | 25,000 | 7.68 | 192.0K | 0 | — | ↗ |
| 2011-07-25 | Stevens David R | Director | D-Return | D | Stock Option (Right to Buy) | 100,000 | 5.55 | 555.0K | 0 | — | ↗ |
| 2011-06-08 | Stevens David R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-05-18 | Wingerter Donald B Jr | Director / Officer | — | D | Stock Option (right to buy) | 600,000 | 1.03 | 618.0K | 0 | — | ↗ |
| 2011-05-18 | McGregor Mark D | Officer | — | D | Stock Option (right to buy) | 100,000 | 2.50 | 250.0K | 0 | — | ↗ |
| 2011-05-18 | MACALUSO MICHAEL | Director | — | D | Common Stock | 0 | 0.00 | — | 4,545 | — | ↗ |
| 2011-05-18 | Giles Richard B | Director | — | D | Common Stock | 0 | 0.00 | — | 59,585 | — | ↗ |
| 2011-05-18 | COELHO PHILIP H | Director | — | D | Common Stock | 0 | 0.00 | — | 4,545 | — | ↗ |
| 2011-05-18 | CLIFT VAUGHAN LENNOX | Officer | — | D | Stock Option (right to buy) | 365,000 | 1.03 | 376.0K | 0 | — | ↗ |
| 2011-05-18 | Bar-Or David | Director / Officer | — | D | Stock Option (right to buy) | 700,000 | 1.03 | 721.0K | 0 | — | ↗ |
| 2011-03-31 | Giles Richard B | Director | D-Return | D | Stock Option (Right to Buy) | 150,000 | 2.50 | 375.0K | 0 | — | ↗ |
| 2011-03-31 | COELHO PHILIP H | Director | D-Return | D | Stock Option (Right to Buy) | 150,000 | 2.50 | 375.0K | 0 | — | ↗ |
| 2011-02-28 | MACALUSO MICHAEL | Director | — | D | Warrant to purchase common stock (right to buy) | 27,379 | 1.75 | 47.9K | 0 | — | ↗ |
| 2011-02-28 | Giles Richard B | Director | — | D | Warrant to purchase common stock (right to buy) | 11,918 | 1.75 | 20.9K | 0 | — | ↗ |
| 2011-01-03 | Giles Richard B | Director | — | I | Stock Option (right to buy) | 40,000 | 2.20 | 88.0K | 0 | — | ↗ |
| 2010-08-27 | MACALUSO MICHAEL | Director | — | D | Stock Option (right to buy) | 330,000 | 1.70 | 561.0K | 0 | — | ↗ |
| 2010-08-27 | Giles Richard B | Director | — | D | Stock Option (right to buy) | 30,000 | 1.70 | 51.0K | 0 | — | ↗ |
| 2010-08-27 | COELHO PHILIP H | Director | — | D | Stock Option (right to buy) | 30,000 | 1.70 | 51.0K | 0 | — | ↗ |
| 2010-08-12 | MACALUSO MICHAEL | Director | — | D | Stock Option (right to buy) | 220,000 | 1.03 | 226.6K | 0 | — | ↗ |
| 2010-08-12 | Giles Richard B | Director | — | D | Stock Option (right to buy) | 220,000 | 1.03 | 226.6K | 0 | — | ↗ |
| 2010-08-12 | COELHO PHILIP H | Director | — | D | Stock Option (right to buy) | 195,000 | 1.03 | 200.9K | 0 | — | ↗ |
| 2010-08-12 | Bar-Or David | Director / Officer | — | D | Stock Option (right to buy) | 400,000 | 1.03 | 412.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.14M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Michael A. Martino CEO | 548.1K | — | — | 120.0K | — | — | 668.1K | 17.96% | ↗ |
| 2 | 2022 | Daniel G. Stokely CFO | 335.0K | — | — | — | — | 11.7K | 346.7K | 0.00% | ↗ |
| 3 | 2022 | Holli Cherevka Former President/COO | 210.5K | — | — | — | — | 4.4K | 214.9K | 0.00% | ↗ |
| 4 | 2021 | Michael Macaluso Former CEO | 356.8K | — | 1.56M | — | — | — | 1.91M | 81.37% | ↗ |
| 5 | 2021 | Holli Cherevka Former President/COO | 301.6K | 5.0K | 820.0K | — | — | — | 1.13M | 72.79% | ↗ |
| 6 | 2021 | Daniel G. Stokely CFO | 296.4K | 5.0K | 549.4K | — | — | — | 850.8K | 64.58% | ↗ |
| 7 | 2021 | Michael A. Martino CEO | 60.4K | — | — | 700.3K | — | — | 760.6K | 92.07% | ↗ |
| 8 | 2020 | Michael Macaluso CEO, effective January 2012 | 300.0K | 157.0K | — | 311.1K | — | — | 768.1K | 40.50% | ↗ |
| 9 | 2020 | Michael Macaluso Former CEO | 300.0K | 157.0K | — | 311.1K | — | — | 768.1K | 40.50% | ↗ |
| 10 | 2020 | Daniel G. Stokely CFO, effective July 2019 | 285.0K | 56.7K | — | 44.7K | — | 77.8K | 464.2K | 9.62% | ↗ |
| 11 | 2020 | Daniel G. Stokely CFO | 285.0K | 56.7K | — | 44.7K | — | 77.8K | 464.2K | 9.62% | ↗ |
| 12 | 2020 | Holli Cherevka COO, effective September 2017 | 280.0K | 7.0K | — | 98.8K | — | 1.0K | 386.8K | 25.53% | ↗ |
| 13 | 2020 | Holli Cherevka Former President/COO | 280.0K | 7.0K | — | 98.8K | — | 1.0K | 386.8K | 25.53% | ↗ |
| 14 | 2019 | Holli Cherevka COO, effective September 2017 | 223.3K | 55.0K | — | 88.7K | — | — | 367.1K | 24.17% | ↗ |
| 15 | 2019 | Michael Macaluso CEO, effective January 2012 | 300.0K | 5.0K | — | — | — | — | 305.0K | 0.00% | ↗ |
| 16 | 2019 | Daniel G. Stokely CFO, effective July 2019 | 119.7K | 5.0K | — | 149.1K | — | 30.5K | 304.4K | 49.00% | ↗ |
| 17 | 2019 | Thomas E. Chilcott Former CFO, resigned June 2019 | 101.0K | — | — | 39.0K | — | 161.0K | 301.0K | 12.96% | ↗ |
| 18 | 2018 | Michael Macaluso Chief Executive Officer and Chairman effective January 2012 | 300.0K | 5.0K | — | — | — | — | 305.0K | 0.00% | ↗ |
| 19 | 2018 | Michael Macaluso CEO, effective January 2012 | 300.0K | 5.0K | — | — | — | — | 305.0K | 0.00% | ↗ |
| 20 | 2018 | Thomas E. Chilcott Former Chief Financial Officer effective June 2017 | 225.0K | 30.0K | — | 34.5K | — | — | 289.5K | 11.91% | ↗ |
| 21 | 2018 | Thomas E. Chilcott Former CFO, resigned June 2019 | 225.0K | 30.0K | — | 34.0K | — | — | 289.0K | 11.76% | ↗ |
| 22 | 2018 | David Bar-Or, M.D. Former Chief Scientific Officer and Chairman | 228.2K | — | — | — | — | — | 228.2K | 0.00% | ↗ |
| 23 | 2018 | Holli Cherevka Chief Operating Officer effective September 2017 | 200.0K | 5.0K | — | 22.4K | — | — | 227.4K | 9.84% | ↗ |
| 24 | 2018 | Holli Cherevka COO, effective September 2017 | 200.0K | 5.0K | — | 22.0K | — | — | 227.0K | 9.69% | ↗ |
| 25 | 2017 | Current Named Executive Officers Michael Macaluso Chief Executive Officer effective January 2012 | 300.0K | 5.0K | — | 268.0K | — | — | 573.0K | 46.77% | ↗ |
| 26 | 2017 | Michael Macaluso Chief Executive Officer and Chairman effective January 2012 | 300.0K | 5.0K | — | 268.0K | — | — | 573.0K | 46.77% | ↗ |
| 27 | 2017 | Thomas E. Chilcott Chief Financial Officer effective June 2017 | 166.5K | 55.0K | — | 170.4K | — | — | 391.8K | 43.48% | ↗ |
| 28 | 2017 | Thomas E. Chilcott Former Chief Financial Officer effective June 2017 | 166.5K | 55.0K | — | 170.4K | — | — | 391.8K | 43.48% | ↗ |
| 29 | 2017 | David Bar-Or, M.D. Former Chief Scientific Officer and Chairman | 300.0K | 5.0K | — | 46.7K | — | — | 351.7K | 13.29% | ↗ |
| 30 | 2017 | Holli Cherevka Chief Operating Officer effective September 2017 | 187.2K | 45.0K | — | 91.9K | — | — | 324.1K | 28.35% | ↗ |
| 31 | 2017 | Holli Cherevka Chief Operating Officer effective September 2017 Formerly Named Executive Officers | 187.2K | 45.0K | — | 91.9K | — | — | 324.1K | 28.35% | ↗ |
| 32 | 2017 | Gregory A. Gould Former Chief Financial Officer | 114.6K | — | — | — | — | 31.8K | 146.4K | 0.00% | ↗ |
| 33 | 2016 | Gregory A. Gould Chief Financial Officer since June 2014 | 250.0K | 5.0K | — | 128.2K | — | — | 383.2K | 33.45% | ↗ |
| 34 | 2016 | Gregory A. Gould Former Chief Financial Officer | 250.0K | 5.0K | — | 128.2K | — | — | 383.2K | 33.45% | ↗ |
| 35 | 2016 | Vaughan Clift, M.D. Former Chief Regulatory Affairs Officer | 145.8K | — | — | 12.4K | — | 161.9K | 320.1K | 3.88% | ↗ |
| 36 | 2016 | Vaughan Clift, M.D. Chief Regulatory Affairs Officer | 145.8K | — | — | 12.4K | — | 161.9K | 320.1K | 3.88% | ↗ |
| 37 | 2016 | Current Named Executive Officers Michael Macaluso Chief Executive Officer effective January 2012 | 300.0K | 5.0K | — | — | — | — | 305.0K | 0.00% | ↗ |
| 38 | 2016 | David Bar-Or, M.D. Former Chief Scientific Officer and Chairman | 300.0K | 5.0K | — | — | — | — | 305.0K | 0.00% | ↗ |
| 39 | 2016 | David Bar-Or, M.D. Chief Scientic Officer and Former Chairman | 300.0K | 5.0K | — | — | — | — | 305.0K | 0.00% | ↗ |
| 40 | 2016 | Current Named Exective Officers Michael Macaluso Chief Executive Officer effective January 2012 | 300.0K | 5.0K | — | — | — | — | 305.0K | 0.00% | ↗ |
| 41 | 2016 | Mark D. McGregor Chief Financial Officer since April 2011 | — | — | — | 20.8K | — | — | 20.8K | 100.00% | ↗ |
| 42 | 2016 | Mark D. McGregor Former Chief Financial Officer | — | — | — | 20.8K | — | — | 20.8K | 100.00% | ↗ |
| 43 | 2015 | Joshua R. Disbrow Former Chief Operating Officer and Chief Executive Officer of Aytu BioScience, Inc. | 255.6K | 122.5K | — | 691.9K | — | 558.7K | 1.63M | 42.48% | ↗ |
| 44 | 2015 | Gregory A. Gould Former Chief Financial Officer | 250.0K | 98.8K | — | 212.2K | — | 232.8K | 793.7K | 26.73% | ↗ |
| 45 | 2015 | Gregory A. Gould Chief Financial Officer since June 2014 | 250.0K | 98.8K | — | 212.2K | — | 232.8K | 793.7K | 26.73% | ↗ |
| 46 | 2015 | David Bar-Or, M.D. Chief Scientic Officer and Former Chairman | 300.0K | 5.0K | — | — | — | 224.6K | 529.6K | 0.00% | ↗ |
| 47 | 2015 | David Bar-Or, M.D. Former Chief Scientific Officer and Chairman | 300.0K | 5.0K | — | — | — | 224.6K | 529.6K | 0.00% | ↗ |
| 48 | 2015 | Current Named Exective Officers Michael Macaluso Chief Executive Officer effective January 2012 | 300.0K | 5.0K | — | — | — | 108.4K | 413.4K | 0.00% | ↗ |
| 49 | 2015 | Current Named Executive Officers Michael Macaluso Chief Executive Officer effective January 2012 | 300.0K | 5.0K | — | — | — | 108.4K | 413.4K | 0.00% | ↗ |
| 50 | 2015 | Vaughan Clift, M.D. Chief Regulatory Affairs Officer | 250.0K | 5.0K | — | — | — | — | 255.0K | 0.00% | ↗ |
| 51 | 2015 | Vaughan Clift, M.D. Former Chief Regulatory Affairs Officer | 250.0K | 5.0K | — | — | — | — | 255.0K | 0.00% | ↗ |
| 52 | 2015 | Mark D. McGregor Former Chief Financial Officer | — | — | — | 125.9K | — | — | 125.9K | 100.00% | ↗ |
| 53 | 2015 | Mark D. McGregor Chief Financial Officer since April 2011 | — | — | — | 125.9K | — | — | 125.9K | 100.00% | ↗ |
| 54 | 2014 | David Bar-Or, M.D. Chief Scientic Officer and Former Chairman | 300.0K | 5.0K | — | 1.54M | — | — | 1.84M | 83.46% | ↗ |
| 55 | 2014 | Gregory A. Gould Chief Financial Officer since June 2014 | 138.5K | 5.0K | — | 1.44M | — | 21.6K | 1.60M | 89.69% | ↗ |
| 56 | 2014 | Gregory A. Gould Chief Financial Officer | 138.5K | 5.0K | — | 1.44M | — | 21.6K | 1.60M | 89.69% | ↗ |
| 57 | 2014 | Current Named Executive Officers Michael Macaluso Chief Executive Officer | 300.0K | 155.0K | — | 1.10M | — | — | 1.55M | 70.65% | ↗ |
| 58 | 2014 | Current Named Exective Officers Michael Macaluso Chief Executive Officer effective January 2012 | 300.0K | 155.0K | — | 1.10M | — | — | 1.55M | 70.65% | ↗ |
| 59 | 2014 | Vaughan Clift, M.D. Former Chief Regulatory Affairs Officer | 250.0K | 5.0K | — | 872.1K | — | — | 1.13M | 77.37% | ↗ |
| 60 | 2014 | Vaughan Clift, M.D. Chief Regulatory Affairs Officer | 250.0K | 5.0K | — | 872.1K | — | — | 1.13M | 77.37% | ↗ |
| 61 | 2014 | Joshua R. Disbrow Former Chief Operating Officer and Chief Executive Officer of Aytu BioScience, Inc. | 245.0K | 180.0K | — | — | — | — | 425.0K | 0.00% | ↗ |
| 62 | 2014 | Mark D. McGregor Chief Financial Officer since April 2011 | 103.1K | 29.0K | — | — | — | 75.0K | 207.1K | 0.00% | ↗ |
| 63 | 2014 | Mark D. McGregor Former Chief Financial Officer | 103.1K | 29.0K | — | — | — | 75.0K | 207.1K | 0.00% | ↗ |
| 64 | 2013 | David Bar-Or, M.D. Chief Scientific Officer and Former Chairman | 300.0K | 155.0K | — | 469.4K | — | — | 924.4K | 50.78% | ↗ |
| 65 | 2013 | David Bar-Or, M.D. Chief Scientic Officer and Former Chairman | 300.0K | 155.0K | — | 469.4K | — | — | 924.4K | 50.78% | ↗ |
| 66 | 2013 | Vaughan Clift, M.D. Former Chief Regulatory Affairs Officer | 250.0K | 130.0K | — | 266.0K | — | — | 646.0K | 41.17% | ↗ |
| 67 | 2013 | Vaughan Clift, M.D. Chief Regulatory Affairs Officer | 250.0K | 130.0K | — | 266.0K | — | — | 646.0K | 41.17% | ↗ |
| 68 | 2013 | Mark D. McGregor Former Chief Financial Officer | 152.2K | 20.0K | — | 212.7K | — | — | 384.9K | 55.26% | ↗ |
| 69 | 2013 | Mark D. McGregor Chief Financial Officer since April 2011 | 152.2K | 20.0K | — | 212.7K | — | — | 384.9K | 55.26% | ↗ |
| 70 | 2013 | Michael Macaluso Chief Executive Officer | 221.3K | 155.0K | — | — | — | — | 376.3K | 0.00% | ↗ |
| 71 | 2013 | Current Named Exective Officers Michael Macaluso Chief Executive Officer effective January 2012 | 221.3K | 155.0K | — | — | — | — | 376.3K | 0.00% | ↗ |
| 72 | 2013 | Current Named Executive Officers Michael Macaluso Chief Executive Officer | 221.3K | 155.0K | — | — | — | — | 376.3K | 0.00% | ↗ |
| 73 | 2013 | Joshua R. Disbrow Chief Operating Officer | 229.0K | 127.5K | — | — | — | — | 356.5K | 0.00% | ↗ |
| 74 | 2013 | Joshua R. Disbrow Former Chief Operating Officer and Chief Executive Officer of Aytu BioScience, Inc. | 229.0K | 127.5K | — | — | — | — | 356.5K | 0.00% | ↗ |
| 75 | 2012 | Joshua R. Disbrow Chief Operating Officer since December, 2012 Former Named Executive Officers | 11.4K | — | — | 1.17M | — | — | 1.18M | 99.03% | ↗ |
| 76 | 2012 | Joshua R. Disbrow Chief Operating Officer | 11.4K | — | — | 1.04M | — | — | 1.05M | 98.92% | ↗ |
| 77 | 2012 | Joshua R. Disbrow Former Chief Operating Officer and Chief Executive Officer of Aytu BioScience, Inc. | 11.4K | — | — | 1.04M | — | — | 1.05M | 98.92% | ↗ |
| 78 | 2012 | David Bar-Or, M.D. Chief Scientific Officer and Former Chairman | 300.0K | 105.0K | — | 407.6K | — | — | 812.6K | 50.16% | ↗ |
| 79 | 2012 | David Bar-Or, M.D. Chief Scientic Officer and Former Chairman | 300.0K | 105.0K | — | 407.6K | — | — | 812.6K | 50.16% | ↗ |
| 80 | 2012 | Michael Macaluso Chief Executive Officer | 190.9K | 5.0K | — | 509.6K | — | — | 705.5K | 72.23% | ↗ |
| 81 | 2012 | Current Named Executive Officers Michael Macaluso Chief Executive Officer | 190.9K | 5.0K | — | 509.6K | — | — | 705.5K | 72.23% | ↗ |
| 82 | 2012 | Michael Macaluso Chief Executive Officer effective January 2012 | 190.9K | 5.0K | — | 509.6K | — | — | 705.5K | 72.23% | ↗ |
| 83 | 2012 | Donald B. Wingerter, Jr. Chief Executive Officer to December 2011 | 555.7K | 48.0K | — | — | — | — | 603.7K | 0.00% | ↗ |
| 84 | 2012 | Vaughan Clift, M.D. Chief Regulatory Affairs Officer | 250.0K | 5.0K | — | 305.7K | — | — | 560.7K | 54.52% | ↗ |
| 85 | 2012 | Mark D. McGregor Former Chief Financial Officer | 150.0K | 5.0K | — | 191.3K | — | — | 346.3K | 55.24% | ↗ |
| 86 | 2012 | Mark D. McGregor Chief Financial Officer since April, 2011 | 150.0K | 5.0K | — | 152.9K | — | — | 307.9K | 49.65% | ↗ |
| 87 | 2012 | Bruce G. Miller Former Chief Financial Officer and Chief Operating Officer and Chief Executive Officer | 125.0K | — | — | — | — | — | 125.0K | 0.00% | ↗ |
| 88 | 2011 | Donald B. Wingerter, Jr. Former Chief Executive Officer | 242.5K | 71.3K | — | — | — | — | 313.8K | 0.00% | ↗ |
| 89 | 2011 | Donald B. Wingerter, Jr. Chief Executive Officer to December 2011 | 242.5K | 71.3K | — | — | — | — | 313.8K | 0.00% | ↗ |
| 90 | 2011 | David Bar-Or, M.D. Chief Scientific Officer | 281.9K | 5.0K | — | — | — | — | 286.9K | 0.00% | ↗ |
| 91 | 2011 | David Bar-Or, M.D. Chief Scientific Officer and Former Chairman | 281.9K | 5.0K | — | — | — | — | 286.9K | 0.00% | ↗ |
| 92 | 2011 | Mark D. McGregor Former Chief Financial Officer | 111.9K | 5.0K | — | 155.4K | — | — | 272.4K | 57.07% | ↗ |
| 93 | 2011 | Mark D. McGregor Chief Financial Officer since April 2011 Former Named Executive Officers | 119.9K | 5.0K | — | 155.4K | — | — | 272.4K | 57.07% | ↗ |
| 94 | 2011 | Mark D. McGregor Chief Financial Officer since April, 2011 | 119.9K | 5.0K | — | 155.4K | — | — | 272.4K | 57.07% | ↗ |
| 95 | 2011 | Vaughan Clift, M.D. Chief Regulatory Affairs Officer | 228.0K | 5.0K | — | — | — | — | 233.0K | 0.00% | ↗ |
| 96 | 2011 | Bruce G. Miller Former Chief Financial Officer and Chief Operating Officer and Chief Executive Officer | 180.0K | 5.0K | — | — | — | — | 185.0K | 0.00% | ↗ |
| 97 | 2010 | David Bar-Or, M.D. Chief Scientific Officer and Former Chairman | 227.5K | — | — | 452.0K | — | — | 679.5K | 66.52% | ↗ |
| 98 | 2010 | David Bar-Or, M.D. Chief Scientific Officer | 227.5K | — | — | 452.0K | — | — | 679.5K | 66.52% | ↗ |
| 99 | 2010 | Donald B. Wingerter, Jr. Chief Executive Officer to December 2011 | 145.3K | 29.0K | — | 385.2K | — | — | 559.5K | 68.84% | ↗ |
| 100 | 2010 | Donald B. Wingerter, Jr. Former Chief Executive Officer | 145.3K | 29.0K | — | 385.2K | — | — | 559.5K | 68.84% | ↗ |
| 101 | 2010 | Vaughan Clift, M.D. Chief Regulatory Affairs Officer | 198.0K | 29.5K | — | 235.7K | — | — | 463.2K | 50.88% | ↗ |
| 102 | 2010 | Bruce G. Miller Former Chief Financial Officer and Chief Operating Officer and Chief Executive Officer | 180.0K | 10.0K | — | — | — | — | 190.0K | 0.00% | ↗ |
| 103 | 2009 | David Bar-Or, M.D. Chief Scientific Officer | 227.5K | — | — | — | — | — | 227.5K | 0.00% | ↗ |
| 104 | 2009 | Bruce G. Miller Former Chief Financial Officer and Chief Operating Officer and Chief Executive Officer | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 105 | 2009 | Vaughan Clift, M.D. Chief Regulatory Affairs Officer | 82.5K | — | — | — | — | — | 82.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael A. Martino | Chief Executive Officer, Chief Financial Officer, General Secretary & Director | 550.0K | male |
| David Bar-Or | Founder & Chairman of Scientific Advisory Board | 145.6K | — |
| April Ramirez | Clinical Trial Manager | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AMPE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
